Table 2. Characteristics of the squamous cell carcinoma patients included in the pooled analysis (n = 115).
| n | % | |
|---|---|---|
| Gender | 100 | |
| Male | 63 | 63.0 |
| Female | 36 | 37.0 |
| Age(years) | 82 | |
| Median | 61.5 | |
| Range | 29-82 | |
| ECOG PS | 59 | |
| < 2 | 42 | 71.2 |
| ≥ 2 | 17 | 28.8 |
| Smoking status | 95 | |
| Smoker(current/former) | 51 | 53.7 |
| Non-smoker(never) | 44 | 46.3 |
| EGFR mutation type | 103 | |
| 19-DEL | 55 | 53.4 |
| L858R | 31 | 30.1 |
| Other mutations | 17 | 16.5 |
| Prior chemotherapy | 82 | |
| 0 | 27 | 32.9 |
| ≥ 1 | 55 | 67.1 |
| EGFR-TKI treatment | 86 | |
| Gefitinib | 58 | 67.4 |
| Erlotinib | 24 | 27.9 |
| Icotinib | 4 | 4.7 |
| Efficacy of EGFR-TKIs | 115 | |
| CR/PR | 45 | 39.1 |
| SD | 37 | 32.2 |
| PD | 33 | 28.7 |
ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.